Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir alafenamide or spironolactone for fatigue in relapsing multiple sclerosis
ACTRN12624000423516Phase 3Not yet recruiting
- Sponsor
- The University of Sydney
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Spironolactone, Tenofovir alafenamide and Placebo (3 arms). Primary endpoint: Fatigue. Planned start May 2024; status: not yet recruiting.
02
Drugs
spironolactonetenofovir alafenamide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12624000423516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000423516.